Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia | MicrobiomeTrials← Back to trialsNCT06797401
Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-01-28Est. Completion: 2027-05-31
Enrollment target: 120 participants Locations- Lunds Universitetssjukhus, Lund, Sweden
- Ribocure Clinic/Ribocure Pharmaceuticals AB, Mölndal, Sweden
- AkardoMedSite, Stockholm, Sweden
- Akademiska Sjukhuset Uppsala, Uppsala, Sweden
Other microbiome trials you might be interested in
Non-alcoholic Fatty Liver Disease (NAFLD)Dyslipidaemia
Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by i…
Melbourne, AustraliaEst. completion Dec 2026
Phlegm-Dampness Syndrome
Dyslipidemia (DL) is a metabolic disorder characterized by abnormal levels of blood lipids and is an important risk fact…
Hồ Chí Minh, VietnamCompleted Jun 10, 2026